# Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma

> **NCT00354107** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 5 (actual)

## Conditions studied

- Anaplastic Large Cell Lymphoma
- Recurrent Childhood Anaplastic Large Cell Lymphoma

## Interventions

- **BIOLOGICAL:** monoclonal antibody SGN-30
- **DRUG:** therapeutic hydrocortisone
- **DRUG:** ifosfamide
- **DRUG:** carboplatin
- **DRUG:** etoposide
- **DRUG:** methotrexate
- **DRUG:** cytarabine
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00354107
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-01
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2018-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00354107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00354107, "Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00354107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*